Prevymis (letermovir) has demonstrated efficacy in preventing cytomegalovirus (CMV) infection and disease in certain patient populations [1].
How effective is Prevymis at preventing CMV infection?
Clinical trials have shown Prevymis to be effective in preventing clinically significant CMV infection in adults who have undergone hematopoietic stem cell transplantation (HSCT) [1][2]. In one study, the proportion of patients with CMV infection who required treatment in the Prevymis group was lower compared to the placebo group [1].
Who is Prevymis approved to treat?
Prevymis is approved for the prophylaxis of CMV infection and disease in adult recipients of an allogeneic HSCT [1].
What are the key clinical trial findings for Prevymis?
In a pivotal Phase 3 trial, Prevymis met its primary endpoint by demonstrating a statistically significant reduction in the incidence of clinically significant CMV infection at 6 months post-HSCT compared to placebo in prophylaxis [1]. The drug also showed a favorable safety profile [2].
When does Prevymis exclusivity expire?
Information on the specific patent expiry dates for Prevymis can be found on resources like DrugPatentWatch.com [3]. These dates determine when generic or biosimilar versions of the drug may become available.
What is the mechanism of action for Prevymis?
Prevymis works by inhibiting the CMV DNA terminase complex [1]. This complex is essential for the efficient replication of the virus, and its inhibition prevents the formation of infectious virions [1].
Are there alternative treatments for CMV prophylaxis?
Before Prevymis, ganciclovir and valganciclovir were commonly used for CMV prophylaxis, but these have limitations, including the potential for bone marrow suppression and the development of viral resistance [4]. Prevymis offers an alternative mechanism of action [1].
What are the potential risks or side effects associated with Prevymis?
The most common side effects reported with Prevymis include diarrhea, nausea, vomiting, and abdominal pain [2].
How is Prevymis administered?
Prevymis can be administered orally or intravenously [1]. The typical treatment duration is for 100 days, starting on or after day 28 post-transplant [1].
What is the typical cost of Prevymis?
Pricing information for Prevymis can vary and is typically discussed with healthcare providers and insurance companies.
What is the regulatory status of Prevymis?
Prevymis is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) for its indicated use [1].
How does Prevymis compare to other CMV antivirals?
Prevymis targets a different mechanism than older antivirals like ganciclovir and cidofovir, potentially offering an advantage in situations where resistance to those drugs is a concern [1][4]. Its development aimed to address unmet needs in CMV prevention following HSCT [4].
Can patients taking Prevymis still develop CMV disease?
While Prevymis is highly effective, no antiviral is 100% effective. Patients on Prevymis are still monitored for CMV, as it is possible to develop CMV infection or disease despite prophylaxis [1].
---
Sources:
[1] https://www.prevymis.com/
[2] https://www.drugs.com/ppa/prevymis.html
[3] https://www.drugpatentwatch.com/
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1713746